Pulmofib 801 mg (Tablet)
Unit Price: ৳ 125.00 (1 x 6: ৳ 750.00)
Strip Price: ৳ 750.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Pirfenidone |
| Company | Beacon pharmaceuticals plc |
| Also available as |
Indications
- Treatment of mild to moderate Idiopathic Pulmonary Fibrosis (IPF) in adults
Pharmacology
- Anti-inflammatory properties
- Antioxidant properties
- Anti-fibrotic properties
- Improves lung function
- Reduces acute exacerbations in IPF patients
- Suppression of TGF-β1
- Downregulation of pro-inflammatory cytokines
- Inhibition of inflammatory cells and pulmonary vascular permeability
Dosage & Administration
- Oral route of administration with food
- Initial titration dosing over a 14-day period
- Recommended daily dose of nine 267 mg tablets or three 801 mg tablets per day
- Dose adjustments for gastrointestinal events
- Dose adjustments for photosensitivity reaction or rash
- Dose adjustments related to hepatic function
Interaction
- Moderate and strong CYP1A2 inhibitors increase systemic exposure
- Discontinuation or reduction of fluvoxamine prior to administration
- Consideration of dosage reduction with use of ciprofloxacin
- Reduced incidence of adverse reactions when taken with food
Contraindications
- Hypersensitivity to active substance or excipients
- Concomitant use of fluvoxamine
- Severe hepatic impairment or end-stage liver disease
- Severe renal impairment or end-stage renal disease requiring dialysis
Side Effects
- Common: nausea, rash, abdominal pain, upper respiratory tract infection, diarrhea, fatigue, headache, dyspepsia, dizziness, vomiting, anorexia, and more
- Rare: photosensitivity reaction, decreased appetite, pruritus, asthenia, dysgeusia, non-cardiac chest pain
Pregnancy & Lactation
- Preferable to avoid use during pregnancy due to potential risk to fetus
- Unknown excretion in human milk, potential risk to the suckling child
- No effects on fertility and reproductive performance in rats at dosages up to 1000 mg/kg/day
Precautions & Warnings
- Monitoring of liver enzymes
- Avoidance of sunlight and sunlamps
- Wearing sunscreen and protective clothing
- Monitoring for gastrointestinal disorders
- Use in special populations: children & adolescents, hepatic impairment, renal impairment, smokers
Use in Special Populations
- Safety and effectiveness not known in children & adolescents
- Not recommended for severe hepatic impairment or end-stage renal disease patients
- Decreased exposure noted in smokers
Overdose Effects
- Limited clinical experience with overdose
- Adverse reactions consistent with most frequently reported for the product
Therapeutic Class
- Immunosuppressant
Storage Conditions
- Cool and dry storage
- Protection from light and moisture
- Keep out of reach of children